Proviral HTV-1 dynamics and evolution in patients receiving efficient long-term antiretroviral combination therapy

HIV Medicine

Volumn 1, Issue 4, 2000, Pages 205-211

  Birk, M ^a,b   Aleman, S ^b   Visco Comandini, U ^a,c   Sonnerborg, A ^a,b  

^a Divisions of Clinical Virology   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Antiretroviral therapy; HIV 1 DNA; HIV 1 RNA; Viral evolution

Indexed keywords

PRIMER DNA; VIRUS DNA; VIRUS RNA;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BLOOD; DRUG EFFECT; FEMALE; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MOLECULAR GENETICS; POLYMERASE CHAIN REACTION; TIME; TREATMENT OUTCOME;

ADULT; AMINO ACID SEQUENCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DNA PRIMERS; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMAN; MALE; MIDDLE AGE; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; RNA, VIRAL; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034303872     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2000.00030.x     Document Type: Article

References (23)

1. Mitsuya H, Weinhold KJ, Furman PA etal 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type 111/lymphadenopathy-assodated virus in vitro. Proc Natl Acad Sei USA 1985; 82: 7096-7100.
2. Finzi D, Hermankova M, Pierson T etal Identification of a reservoir for HfV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-1300.
3. Erali M, Hillyard DR. Evaluation of the ultrasensitive Roche amplicor H1V-1 monitor assay for quantitation of human immunodeficiency virus type 1 RNA. J C/in Microbiol 1999; 37: 792-795.
4. Ruiz L, van Lunzen J, Arno A etal. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 1999; 13: F1-F8.
5. Cavert W, Notermans DW, Staskus K etal. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276: 960-964.
6. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4 (+) T cells during primary HIV-1 infection. Proc Natl Acad Sei USA 1998; 95: 8869-8873.
7. Zhang L, Ramratnam B, Tenner-Racz K etal. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340: 1605-1613.
8. Domadula G, Zhang H, VanUitert B et al Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy [see comments]. JAMA 1999; 282: 1627-1632.
9. Furtado MR, Callaway DS, Phair JP etal. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N EnglJ Med 1999; 340: 1614-1622.
10. Ramratnam B, Mittler JE, Zhang L etal The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000; 6: 82-85.
11. Finzi D, Blankson J, Siliciano JD etal. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5: 512-517.
12. Sharkey ME, Teo I, Greenough T eral. Persistence of episomal IirV-1 infection intermediates in patients on highly active antiretroviral therapy. Nat Med 2000; 6: 76-81.
13. Gunthard HF, Frost SD, Leigh-Brown AJ etal Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999; 73: 9404-9412.
14. Visco Comandini U, Sonnerborg A, Vahlne A, Yun Z. Quantification of HIV-1 proviral DNA from peripheral blood raononuclear cells using a high throughput four-competitor competitive PCR. J Viml Methods 1997; 69: 171-180.
15. Aleman S, Visco-Comandini U, Lore K, Sonnerborg A. Longterm effects on HIV-1 DNA levels during antiretroviral combination therapy. AIDS Res Hum Retroviruses 1999; 15: 1249-1254.
16. Tamalet C, Lafeuillade A, Fantini J, Poggi C, Yahi N. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy. AIDS 1997; 11:895-901.
17. Perelson AS, Essunger P, Cao Y étal. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387: 188-191.
18. Richman DD, Havlir D, Corbeil J et al. Nevirapine resistance mutations of huma immunodeficiency virus type 1 selected during therapy. J Viml 1994; 68: 1660-1666.
19. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vii-o selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sei USA 1993; 90: B653-5656.
20. Brostrom C, Visco-Comandini U, Yun Z, Sonnerborg A. Longitudinal quantification of human immunodeficiency virus type 1 DNA and RNA in long-term nonprogressors. J Infect Dis 1999; 179: 1542-1548.
21. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993; 365: 671-673.
22. Karlsson AC, Lindback S, Gaines H, Sonnerborg A. Characterization of the viral population during primary HIV-1 infection. AIDS 1998; 12: 839-847.
23. Liu SL, Rodrigo AG, Shankarappa R etal. HIV quasispecies and resampling. Science 1996; 273: 415-416.